HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tofe, A. J. Articles by Francis, M. D. Search for Related Content PubMed PubMed Citation Articles by Tofe, A. J. Articles by Francis, M. D.

In Vitro Stabilization of a Low-Tin Bone-imaging Agent (^99mTc-Sn-HEDP) by Ascorbic Acid

Miami Valley Laboratories, Procter & Gamble Company, Cincinnati, Ohio

Correspondence: For reprints contact: A. J. Tofe, Miami Valley Laboratories, Procter & Gamble Co., P.O. Box 39175, Cincinnati, OH 45247.

ABSTRACT

The presence of oxidants in the ^99mTc-pertechnetate and of oxygen in diagnostic kits containing low concentrations of Sn(II) has a detrimental effect upon in vitro and in vivo stability. Maintaining a nitrogen atmosphere or increasing the Sn(II) concentration inhibits the formation of ^99mTcO₄^-. However, the latter remedy is likely to cause uptake in the reticuloendothelial system and has been associated with false positive or negative brain scans. We used ascorbic acid (an antioxidant) to ensure the in vitro stability with the low-Sn(II) bone agent disodium etidronate. In vitro stability studies by instant thin-layer chromatography, using high-activity generators and "instant pertechnetate," yielded less than 2% free pertechnetate at 24 hr after preparation. Distribution studies in guinea pigs show neither altered distribution of the bone agent nor abnormal distribution of ascorbic acid, suggesting its sole function as a noncomplexing stabilizer.